Yona Geffen
Chief Tech/Sci/R&D Officer bij GAMIDA CELL LTD.
Profiel
Yona Geffen is currently the Vice President-Research & Development at Gamida Cell Ltd.
Prior to this, she was the Chief Executive Officer at Avraham Pharmaceuticals Ltd.
from 2011 to 2016.
She also worked as a Director-Executive Drug Development at BioLineRx Ltd.
Dr. Geffen holds graduate and doctorate degrees from Ben-Gurion University of the Negev.
Actieve functies van Yona Geffen
| Bedrijven | Functie | Begin |
|---|---|---|
| GAMIDA CELL LTD. | Chief Tech/Sci/R&D Officer | 01-12-2020 |
Eerdere bekende functies van Yona Geffen
| Bedrijven | Functie | Einde |
|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Chief Executive Officer | 01-12-2016 |
| BIOLINERX LTD. | Corporate Officer/Principal | - |
Opleiding van Yona Geffen
| Ben-Gurion University of the Negev | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
